Compare Amylx Pharmaceuticals Inc (AMLX) vs Broadcom Inc (AVGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Broadcom Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Broadcom Inc trades at $415.8 (market cap $1.98T). The key difference: Broadcom Inc is far larger — about 750× Amylx Pharmaceuticals Inc's market cap, and Broadcom Inc pays a 0.62% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | AVGO | |
|---|---|---|
Market Cap | $2.64B | $1.98T |
Sector | Health | Technology |
52-Week High | $24.19 | $481.57 |
52-Week Low | $7.82 | $289.60 |
Enterprise Value | $2.39B | $2.02T |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
Broadcom (AVGO) trades at $414.83, down 1.79% on the day, amid strong fundamentals including a 38.85% net income margin and consistent earnings beats. Technical analysis shows a bullish trend with key support at $412 and resistance at $422. The company reported robust cash flow from operations of $27.54 billion in 2025 and projects AI semiconductor revenue exceeding $100 billion by 2027, per CEO Hock Tan's reaffirmed forecast (The Motley Fool, 2026-08-11).
Outlook remains positive with 86% analyst buy ratings and a $510.21 consensus price target, though high valuation multiples (P/E 69.23) and competitive pressures in AI chips pose risks. The stock's growth is supported by booked AI revenue and strong cash generation, offering upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →
